We generate new insights, invest deeply in R&D, and collaborate with scientists around the world.

Scientific Innovation is the foundation for all our products and services.

For us EYE-INSPIRED INNOVATION is all about collaborating with the brightest around the world, gaining insights from patients and clinicians, and translating those insights into improvements in products, patient care, and ultimately life itself.

Legacy & Future

Contact Lens Innovation

Leonardo da Vinci first illustrated the concept of contact lenses in 1508. In his “Codex of the Eye” he described a method of directly altering corneal power. More than 500 years later, Johnson & Johnson Vision embraces this spirit of invention. We introduced the world’s first disposable soft contact lens under the brand name ACUVUE® in 1987 and we continue to be fervently focused on bringing advances to what we consider to be one of the most fascinating wearable technologies of our time — contact lenses.

Refractive Surgery Innovation

Refractive surgeries are thought to have been carried out in ancient Greece. Today, laser technologies have revolutionized vision corrective surgery by providing a degree of safety and precision that was previously unattainable.

A Legacy of Innovation in Cataract Surgery

Cataract surgery, one of the oldest surgical procedures on record, was first documented in the fifth century BC! Today it’s one of the most common surgeries in the U. S. In 2017 Johnson & Johnson acquired Abbott Medical Optics and is a global leader in ophthalmic surgery, including refractive and cataract surgery and intraocular lens (IOL) implants.

Dry Eye Disease Innovation

Dry Eye Disease Innovation

Early in the fifth century, oat herbs were placed on the eye to treat Dry Eye Disease (DED).  Later in the 11th century, topically applied grape wine ashes, vinegar and honey were used. Fortunately, with the help of science, we’ve come a long way since then but there are still more than 340 million people globally who suffer from DED. We also now understand that Meibomian Gland Dysfunction (MGD) is a leading cause of DED, affecting 86% of dry eye patients. As a leader in medical device technologies, Johnson & Johnson Vision is focused on delivering scientific innovation designed specifically for treating MGD and DED.

Innovation: What Does the Future Hold?

Johnson & Johnson Vision envisions a future where preventable vision loss and blindness are relics of the past. A future where access is improved in communities of need. A future where eye care professionals, institutions and industry work together to change the experience for patients. A future where smart-device technologies, computer-assisted surgeries and customization for a patient’s eye health needs become the norm.

To help create this reality, we are making significant investments in new science and technologies as well as insights and analytics. 

Our research agenda addresses a broad spectrum of eye disease - from myopia that often strikes children at a young age through to advanced macular disease. And we have in late-stage development brand new categories of contact lenses that have the potential to deliver benefits beyond vision correction.